HOUSTON, Oct. 15, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical technology
company that has developed a new acoustic shockwave device, today
announced that the Taiwan Intellectual Property Office had issued
our patent entitled, "Taiwan Divisional Patent Application No.
107115437 from TW101125235; Entitled 'APPARATUS AND METHOD FOR
GENERATING THERAPEUTIC SHOCKWAVES AND LASER LIGHT'" by Dr.
Christopher C. Capelli et al.
Additionally, the Japanese Patent Office issued our patent
entitiled, "Japanese Divisional Patent Application No. 2018-008760
from JP 2015-561713 and PCT/US2014/021746; In the name of Soliton,
Inc. and the Board of Regents of the University of Texas System; 'RAPID PULSE
ELECTROHYDRAULIC SHOCKWAVE GENERATOR'" by Dr. Christopher C. Capelli et al.
Dr. Chris Capelli, CEO of
Soliton, said, "We now have 8 patent families and over 60 issued or
pending patents for our Rapid Acoustic Pulse, or 'RAP' device.
Extending our broad patent portfolio to key international markets
has been an important part of our IP strategy. We are pleased to
see the patent offices in Japan
and Taiwan validate our
intellectual property through the issuance of these patents."
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please visit:
http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton to
expand its business to international markets in the future. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under the heading "Risk
Factors" and elsewhere in our offering circular. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/solitons-fda-cleared-rap-device-is-granted-two-additional-key-patents-300938214.html
SOURCE Soliton, Inc.